Glucocorticoid prodrugs for the treatment of nephritis
Shannon Pharmaceuticals, Inc. is an Omaha, Nebraska, start-up company focusing on the development of therapeutic interventions for nephrotic diseases. The company’s lead compound, ZSJ-0228, is a glucocorticoid-based prodrug, which was found to be highly effective in amelioration of nephritis in multiple animal models of lupus and in a model of a rare kidney disorder, focal segmental glomerulosclerosis (FSGS). ZSJ-0228 does not cause side effects commonly associated with glucocorticoids. Extensive preclinical studies on ZSJ-0228 have been performed using initial seed round investment.
Shannon Pharmaceuticals is interested in exploring potential partnering opportunities to move ZSJ-0228 forward for clinical evaluation.